MA28935B1 - Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite - Google Patents

Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite

Info

Publication number: MA28935B1
Authority: MA; Morocco
Prior art keywords: biphenyl; obesity; preparation; treatment; acid derivatives
Prior art date: 2004-10-15

Application number

MA29831A

Other languages

English (en)

Inventor

Roger Smith

Stephen J O'connor

Philip Coish

Derek Lowe

Roger B Clark

Jeffrey Stebbins

Ann-Marie Campbell

Christiana Akuche

Tatiana Shelekhin

Original Assignee

Bayer Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-15

Filing date

2007-04-17

Publication date

2007-10-01

2007-04-17 Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp

2007-10-01 Publication of MA28935B1 publication Critical patent/MA28935B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MA29831A 2004-10-15 2007-04-17 Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite MA28935B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US61897504P	2004-10-15	2004-10-15

Publications (1)

Publication Number	Publication Date
MA28935B1 true MA28935B1 (fr)	2007-10-01

Family

ID=36203612

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA29831A MA28935B1 (fr)	2004-10-15	2007-04-17	Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite

Country Status (21)

Country	Link
US (2)	US7759376B2 (fr)
EP (1)	EP1805156B1 (fr)
JP (1)	JP2008516978A (fr)
KR (1)	KR20070063546A (fr)
CN (1)	CN101087769A (fr)
AT (1)	ATE492542T1 (fr)
AU (1)	AU2005295453A1 (fr)
BR (1)	BRPI0516483A (fr)
CA (1)	CA2583784A1 (fr)
CR (1)	CR9034A (fr)
DE (1)	DE602005025517D1 (fr)
EA (1)	EA200700851A1 (fr)
EC (1)	ECSP077397A (fr)
ES (1)	ES2357015T3 (fr)
IL (1)	IL182218A0 (fr)
MA (1)	MA28935B1 (fr)
MX (1)	MX2007004217A (fr)
NO (1)	NO20072461L (fr)
TN (1)	TNSN07111A1 (fr)
WO (1)	WO2006044775A2 (fr)
ZA (1)	ZA200703002B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ555683A (en)	2004-12-14	2010-09-30	Astrazeneca Ab	Oxadiazole derivatives as dgat inhibitors
AU2006318260B2 (en)	2005-11-21	2012-05-17	Anadys Pharmaceuticals, Inc.	Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one
EP1966221A1 (fr)	2005-12-22	2008-09-10	AstraZeneca AB	Pyrimido-[4,5-]-oxazines pour utilisation en tant qu'inhibiteurs de dgat
SG10201408806UA (en)	2006-03-31	2015-02-27	Novartis Ag	New compounds
DE602007011446D1 (en)	2006-05-30	2011-02-03	Astrazeneca Ab	Substituierte 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a-diacylglycerolacyltransferase
WO2007138304A1 (fr)	2006-05-30	2007-12-06	Astrazeneca Ab	Dérivés du 1,3,4-oxadiazole en tant qu'inhibiteurs de dgat1
KR100811100B1 (ko)	2006-09-27	2008-03-06	한국생명공학연구원	벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko)	2006-09-27	2008-01-16	한국생명공학연구원	인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
PE20080888A1 (es)	2006-10-18	2008-08-26	Novartis Ag	COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
CN101600437A (zh) *	2006-12-11	2009-12-09	诺瓦提斯公司	预防或治疗心肌缺血的方法
CN101678019B (zh)	2007-06-08	2016-03-30	詹森药业有限公司	哌啶/哌嗪衍生物
ES2483898T3 (es) *	2007-06-08	2014-08-08	Janssen Pharmaceutica, N.V.	Derivados de piperidina/piperazina
JO2972B1 (en)	2007-06-08	2016-03-15	جانسين فارماسوتيكا ان. في	Piperidine / piperazine derivatives
JP5443342B2 (ja)	2007-06-08	2014-03-19	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ピペリジン／ピペラジン誘導体
AR066169A1 (es)	2007-09-28	2009-07-29	Novartis Ag	Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
ES2535083T3 (es)	2007-12-20	2015-05-05	Astrazeneca Ab	Compuestos de carbamoilo como inhibidores 190 de DGAT1
SG190620A1 (en)	2008-05-05	2013-06-28	Sanofi Aventis	Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
WO2009147170A2 (fr)	2008-06-05	2009-12-10	Janssen Pharmaceutica Nv	Combinaisons de médicaments comprenant un inhibiteur de dgat et un agoniste de ppar
US20100168079A1 (en) *	2008-12-23	2010-07-01	Daniela Angst	Biaryl Benzylamine Derivatives
EP2389366A1 (fr) *	2009-01-23	2011-11-30	Msd K.K.	Dérivés de benzodiazépin-2-one
WO2010108051A2 (fr)	2009-03-20	2010-09-23	Ligand Pharmaceuticals	Inhibiteurs de diacylglycérol o-acétyltransférase 1 (dgat-1) et leurs utilisations
US8268820B2 (en)	2009-03-26	2012-09-18	Hoffmann-La Roche Inc.	2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
EP2411005A1 (fr)	2009-03-27	2012-02-01	Bristol-Myers Squibb Company	Procédés destinés à prévenir des événements cardiovasculaires indésirables majeurs par des inhibiteurs de la dpp-iv
WO2010146395A1 (fr)	2009-06-19	2010-12-23	Astrazeneca Ab	Carboxamides de pyrazine utiles comme inhibiteurs de la dgat1
AR079022A1 (es) *	2009-11-02	2011-12-21	Sanofi Aventis	Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
AU2010316669B2 (en)	2009-11-05	2014-10-23	Piramal Enterprises Limited	Carboxy oxazole or thiazole compounds as DGAT - 1 inhibitors useful for the treatment of obesity
SG181702A1 (en)	2009-12-16	2012-07-30	Pola Chem Ind Inc	Preventing or ameliorating agent for pigmentation
EP2552441B1 (fr)	2010-03-30	2016-05-04	Novartis AG	Utilisations d'inhibiteurs de dgat1
WO2012150784A2 (fr)	2011-05-03	2012-11-08	한국생명공학연구원	Nouveau dérivé d'indole ou sel pharmaceutiquement acceptable de celui-ci, procédé de préparation de celui-ci, et composition pharmaceutique pour prévenir ou traiter des maladies métaboliques contenant celui-ci en tant que substance active
WO2013055910A1 (fr)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2014039412A1 (fr)	2012-09-05	2014-03-13	Bristol-Myers Squibb Company	Antagonistes du récepteur 1 d'hormone concentrant la mélanine de type pyrrolone ou pyrrolidinone
EP2892896B1 (fr)	2012-09-05	2016-06-29	Bristol-Myers Squibb Company	Antagonistes du récepteur 1 de l'hormone de concentration de pyrrolone ou pyrrolidinone mélanine
WO2014074668A1 (fr)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
EP3174875B1 (fr) *	2014-08-01	2020-08-19	Bayer Pharma Aktiengesellschaft	Procédé pour fabriquer du (4s)-4-(4-cyano-2-méthoxyphényl)-5-éthoxy-2,8-diméthyl-1,4-dihydro-1,6-naphthyridin-3-carboxamide et le purifier en vue de l'utiliser en tant que principe actif pharmaceutique
CN105646510A (zh) *	2014-12-02	2016-06-08	重庆宁牧生态农业有限公司	一种用作抗肥胖剂的化合物
MX2020009604A (es)	2018-03-16	2023-01-25	Anji Pharmaceuticals Inc	Composiciones y metodos para tratar el estre?imiento grave.
US20220304984A1 (en) *	2019-06-12	2022-09-29	Vanderbilt University	Amino acid transport inhibitors and the uses thereof
CN112336718A (zh) *	2020-10-19	2021-02-09	济南大学	一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用
WO2023085931A1 (fr)	2021-11-11	2023-05-19	Koninklijke Nederlandse Akademie Van Wetenschappen	Organoïdes hépatiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4164645B2 (ja) *	2002-08-09	2008-10-15	株式会社大塚製薬工場	Ｄｇａｔ阻害剤
CN1753897A (zh) *	2002-11-22	2006-03-29	日本烟草产业株式会社	稠合双环含氮杂环
AR044152A1 (es) *	2003-05-09	2005-08-24	Bayer Corp	Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

2005
- 2005-10-14 CA CA002583784A patent/CA2583784A1/fr not_active Abandoned
- 2005-10-14 KR KR1020077008522A patent/KR20070063546A/ko not_active Withdrawn
- 2005-10-14 JP JP2007536988A patent/JP2008516978A/ja active Pending
- 2005-10-14 BR BRPI0516483-4A patent/BRPI0516483A/pt not_active IP Right Cessation
- 2005-10-14 EP EP05812611A patent/EP1805156B1/fr not_active Expired - Lifetime
- 2005-10-14 WO PCT/US2005/037215 patent/WO2006044775A2/fr not_active Ceased
- 2005-10-14 US US11/665,317 patent/US7759376B2/en not_active Expired - Fee Related
- 2005-10-14 CN CNA2005800433280A patent/CN101087769A/zh active Pending
- 2005-10-14 DE DE602005025517T patent/DE602005025517D1/de not_active Expired - Lifetime
- 2005-10-14 ES ES05812611T patent/ES2357015T3/es not_active Expired - Lifetime
- 2005-10-14 MX MX2007004217A patent/MX2007004217A/es not_active Application Discontinuation
- 2005-10-14 AU AU2005295453A patent/AU2005295453A1/en not_active Abandoned
- 2005-10-14 EA EA200700851A patent/EA200700851A1/ru unknown
- 2005-10-14 AT AT05812611T patent/ATE492542T1/de not_active IP Right Cessation
2007
- 2007-03-27 IL IL182218A patent/IL182218A0/en unknown
- 2007-03-28 TN TNP2007000111A patent/TNSN07111A1/en unknown
- 2007-03-30 CR CR9034A patent/CR9034A/es not_active Application Discontinuation
- 2007-04-12 ZA ZA200703002A patent/ZA200703002B/xx unknown
- 2007-04-13 EC EC2007007397A patent/ECSP077397A/es unknown
- 2007-04-17 MA MA29831A patent/MA28935B1/fr unknown
- 2007-05-14 NO NO20072461A patent/NO20072461L/no not_active Application Discontinuation
2010
- 2010-07-14 US US12/836,035 patent/US20110118302A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ECSP077397A (es)	2007-05-30
US7759376B2 (en)	2010-07-20
CR9034A (es)	2008-11-18
EP1805156A4 (fr)	2009-06-10
CN101087769A (zh)	2007-12-12
WO2006044775A2 (fr)	2006-04-27
ATE492542T1 (de)	2011-01-15
AU2005295453A1 (en)	2006-04-27
TNSN07111A1 (en)	2008-06-02
KR20070063546A (ko)	2007-06-19
US20110118302A1 (en)	2011-05-19
CA2583784A1 (fr)	2006-04-27
NO20072461L (no)	2007-07-03
EP1805156B1 (fr)	2010-12-22
BRPI0516483A (pt)	2008-09-02
EP1805156A2 (fr)	2007-07-11
US20070265298A1 (en)	2007-11-15
EA200700851A1 (ru)	2007-12-28
DE602005025517D1 (de)	2011-02-03
JP2008516978A (ja)	2008-05-22
IL182218A0 (en)	2007-09-20
ES2357015T3 (es)	2011-04-15
WO2006044775A3 (fr)	2006-06-15
MX2007004217A (es)	2007-06-11
ZA200703002B (en)	2008-08-27

Publication	Publication Date	Title
MA28935B1 (fr)	2007-10-01	Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MXPA05012061A (es)	2006-02-22	Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
EA200700175A1 (ru)	2007-08-31	Композиции и способы лечения воспалительных заболеваний
EA200870391A1 (ru)	2009-06-30	Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
EA200802213A1 (ru)	2009-10-30	Способы лечения заболеваний крови
EP1562897A4 (fr)	2007-06-27	Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
DE60303238D1 (de)	2006-04-06	Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE489957T1 (de)	2010-12-15	Mittel zur behandlung von entzündlichen erkrankungen
EA200900802A1 (ru)	2010-04-30	Способы и композиции для лечения амилоидных заболеваний
NO20092639L (no)	2009-09-11	4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
EA200600078A1 (ru)	2006-08-25	Способы и композиции для лечения амилоидных заболеваний
EA200501771A1 (ru)	2006-06-30	Лиганды каннабиноидных рецепторов и их применения
EA200900203A1 (ru)	2009-06-30	Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA200870019A1 (ru)	2008-12-30	Лактамовые соединения и способы их применения
ATE368031T1 (de)	2007-08-15	Neue gamma secretase inhibitoren
ATE506951T1 (de)	2011-05-15	Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE409176T1 (de)	2008-10-15	1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE478864T1 (de)	2010-09-15	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE538651T1 (de)	2012-01-15	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20076405L (no)	2008-02-11	Anvendelse av 24-nor-UDCA
EP1749532A4 (fr)	2007-08-15	Médicament pour la guérison ou le traitement d'une blessure
DE602005014632D1 (de)	2009-07-09	Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DK1596879T3 (da)	2011-04-11	Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE602004024871D1 (de)	2010-02-11	Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE602005013287D1 (de)	2009-04-23	Zusammensetzung zur behandlung von leder